Phaseline

Targets › IL17A

IL17A (Interleukin-17A): drug programs, companies and trials

13 programs from 12 companies in 35 trials: 14 Phase 3, 9 Phase 4, 7 Phase 1, 5 Phase 2; Immunology, Infectious disease, Oncology; next expected readout Dec 2026.

Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. (UniProt, Q16552)

Open in Phaseline: the race on IL17A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
First Hospital of China Medical UniversityXeligekimab Injection
IL-17A inhibitor monoclonal antibody
IL17APhase 4Palmoplantar Pustulosis (PPP)Dec 2027
NovartisSecukinumab
Interleukin 17A inhibitor
IL17APhase 4Non-radiographic Axial Spondyloarthritis; Hidradenitis Suppurativa (HS); Autoimmunity, Inflammation; Polymyalgia Rheumatica …Feb 2028
Psoriasis Treatment Center of Central New JerseyTaltz
Interleukin-17A (IL-17A) inhibitor
IL17APhase 4Psoriasis–
UCB Biopharma SRLBimekizumab
Interleukin 17A inhibitor; Interleukin-17F inhibitor
IL17A, IL17FPhase 3Hidradenitis Suppurativa; Moderate to Severe Plaque Psoriasis; Palmoplantar Pustulosis; Enthesitis-related Arthritis …Dec 2026
MoonLake ImmunotherapeuticsM-1095
Interleukin 17A inhibitor; Interleukin-17F inhibitor
IL17A, IL17FPhase 3Hidradenitis Suppurativa; Arthritis, PsoriaticJan 2027
Suzhou Suncadia BiopharmaceuticalsVunakizumab (SHR-1314)
Interleukin 17A inhibitor
IL17APhase 3Psoriatic Arthritis; Active Non-radiographic Axial Spondyloarthritis; Lupus Erythematosus, SystemicJan 2027
BiocadNetakimab
IL-17A inhibitor monoclonal antibody
IL17APhase 3Plaque PsoriasisFeb 2028
Eli LillyIxekizumab (LY2439821)
Interleukin 17A inhibitor
IL17APhase 3Juvenile Psoriatic Arthritis; Plaque Psoriasis; Psoriasis Vulgaris; Type1 Diabetes MellitusJan 2029
CelltrionSecukinumab (P55)
Interleukin 17A inhibitor
IL17APhase 3Plaque Psoriasis–
SinocelltechSCT650C
Anti-IL-17A antibody
IL17APhase 2Hidradenitis Suppurativa (HS)Mar 2027
Zura BioTibulizumab (ZB-106)
Tumor necrosis factor ligand superfamily member 13B inhibitor; Interleukin 17A inhibitor
TNFSF13B, IL17APhase 2Hidradenitis Suppurativa (HS); Systemic Sclerosis (SSc)Apr 2027
Taizhou Mabtech PharmaceuticalCMAB015
Interleukin-17A (IL-17A) inhibitor monoclonal antibody
IL17APhase 1Psoriasis–
CelltrionCT-P52
IL-17A inhibitor biosimilar
IL17APhase 1Healthy Participants–

Conditions

Hidradenitis Suppurativa (HS) (3) Psoriasis (3) Plaque Psoriasis (3) Moderate to Severe Plaque Psoriasis (3) Juvenile Psoriatic Arthritis (2) Psoriasis Vulgaris (2) Hidradenitis Suppurativa (2) Arthritis, Psoriatic (2) Psoriatic Arthritis (2) Non-radiographic Axial Spondyloarthritis (1) Autoimmunity, Inflammation (1) Polymyalgia Rheumatica (1)

Modalities

antibody (9), small molecule (2), mixed (1), protein or peptide (1)

Companies

Celltrion (2) Novartis (1) Psoriasis Treatment Center of Central New Jersey (1) MoonLake Immunotherapeutics (1) Suzhou Suncadia Biopharmaceuticals (1) First Hospital of China Medical University (1) Biocad (1) UCB Biopharma SRL (1) Eli Lilly (1) Zura Bio (1) Sinocelltech (1) Taizhou Mabtech Pharmaceutical (1)

Related targets

IL17F (2) TNFSF13B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.